Abiopharma

Labeling changes approved for APOTEX INC. Active ingredient: TIZANIDINE HYDROCHLORIDE. Decision date: 12/16/2025

Labeling changes approved for UNIQUE. Active ingredient: CIPROFLOXACIN HYDROCHLORIDE. Decision date: 12/17/2025

Final approval of ANDA #ANDA #216528 for BORTEZOMIB. Decision date: 12/17/2025

Labeling changes approved for ENCUBE. Active ingredient: TESTOSTERONE. Decision date: 12/17/2025

Labeling changes approved for HOSPIRA. Active ingredient: VINCRISTINE SULFATE. Decision date: 12/17/2025

BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): CHANGES IN INTEREST OF SUBSTANTIAL SHAREHOLDER

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): CHANGES IN INTEREST OF SUBSTANTIAL SHAREHOLDER

Evoke Pharma Inc. (EVOK) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Evoke Pharma, Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Evoke Pharma, Inc. - Common Stock. New value: Evoke Pharma, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Evoke Pharma, Inc. - Common Stock.

PureTech Appoints Robert Lyne as Chief Executive Officer